My Diabetes, My Community
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04970810 |
Recruitment Status :
Active, not recruiting
First Posted : July 21, 2021
Last Update Posted : September 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 2 Diabetes | Behavioral: My Diabetes Goal Behavioral: My Diabetes Goal + CommunityRx | Not Applicable |
To address the needs of older patients with diabetes, multiple organizations have called for a personalized approach to setting risk factor goals and self-care plans. The American Geriatrics Society (AGS) and the American Diabetes Association (ADA) have published recommendations urging individualized glycemic goals (hemoglobin A1C (A1C) <7.5%, <8.0%, or <8.5%) for three strata of older patients (healthy, complex, very complex). The guidelines also acknowledge the importance of addressing socioeconomic risks that are barriers to self-care management such as cost-related non-adherence and food insecurity. Despite widespread agreement by experts, the clinical impact of this highly personalized approach to diabetes care for older adults has been rarely studied in controlled trials. Interventions designed to personalize diabetes care must overcome multiple challenges to implementation including the brief clinical encounter, lack of patient engagement between encounters, and lack of systems to leverage community-based self-care resources.
Investigators propose to address these knowledge and care gaps by studying the integration of two evidence-based interventions designed to engage patients and enhance self-care:. Managing Diabetes to Gain Opportunities for a More Active Life (My Diabetes GOAL) and CommunityRx. The My Diabetes GOAL intervention is designed to engage older patients in personalized goal setting and chronic disease management.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 505 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Masking Description: | This will be a single-blind study, and subjects will blinded to the different group assignment. |
Primary Purpose: | Supportive Care |
Official Title: | My Diabetes, My Community |
Actual Study Start Date : | July 29, 2021 |
Estimated Primary Completion Date : | July 28, 2024 |
Estimated Study Completion Date : | July 28, 2024 |

Arm | Intervention/treatment |
---|---|
No Intervention: Attention Control
Subjects monthly calls similar in structure to the intervention arms, but without support. (attention placebo control)
|
|
Active Comparator: My Diabetes Goal
My Diabetes Goal protocol
|
Behavioral: My Diabetes Goal
Subjects enrolled in the MDG arm will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. |
Active Comparator: My Diabetes Goal + Community Rx
My Diabetes Goal protocol + Community Rx protocol
|
Behavioral: My Diabetes Goal + CommunityRx
Subjects enrolled in the MDG arm + CRx will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. Participants will also receive a HealtheRx (personalized resource "prescriptions") for community organizations. |
- A1c [ Time Frame: Baseline to 12 months ]Change in A1c
- Assessment of personalized diabetes care goal [ Time Frame: Baseline to 12 months ]Investigators will compare diabetes care goals documented in the EHR against the study survey. The possible values will be yes or no goals documented in the EHR.
- Patients' ability to reach personalized goals [ Time Frame: Baseline to 12 months ]Investigators will measure whether or not patients are reaching the goals they have documented in the survey, among those who have set up their personalized goals. The possible values will be yes or no reaching personalized goals.
- Diabetes Self-Efficacy [ Time Frame: Baseline to 12 months ]Evaluate subject self-efficacy through the diabetes empowerment scale.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- History of type 2 diabetes
- Seen in clinic within past year
- A1C>7.5%
- Community dwelling
- Access to personal email address OR internet access
- Speaks and reads English
- Resides in the target geographic region (zip codes)
Exclusion Criteria:
- Unable to consent to study for themselves
- Prior participation in CRxCaregiver, CRxHunger, or My Diabetes GOAL trials

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04970810
United States, Illinois | |
University of Chicago Medicine | |
Chicago, Illinois, United States, 60637 |
Principal Investigator: | Elbert Huang | University of Chicago | |
Principal Investigator: | Stacy Lindau | University of Chicago |
Documents provided by University of Chicago:
Responsible Party: | University of Chicago |
ClinicalTrials.gov Identifier: | NCT04970810 |
Other Study ID Numbers: |
IRB20-0870 1R01DK127961-01 ( U.S. NIH Grant/Contract ) |
First Posted: | July 21, 2021 Key Record Dates |
Last Update Posted: | September 18, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | We do not plan to share IPD with other researchers. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |